NCT06087289
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase 1/2
Role: Lead Sponsor
Start: Apr 26, 2023
Completion: Apr 3, 2025